Evidence map›Paper›PMID 31384394›Full record

ArticleOncotarget2019

CpG promoter hypo-methylation and up-regulation of microRNA-190b in hormone receptor-positive breast cancer.

Elisabet Frick, Thorkell Gudjonsson, Jorunn Eyfjord, Jon Jonasson, Laufey Tryggvadóttir, Olafur Stefansson, Stefan Sigurdsson

Open access · diamondAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncotarget, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.3field-weighted citation impact, top 47% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 6 citations in OpenAlex.

  1. MicroRNA-190b Targets RFWD3 in Estrogen Receptor-Positive Breast Cancer.Breast cancer : basic and clinical research · 2024
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 1 country.

Elisabet FrickCancer Research Laboratory, Biomedical Center, Reykjavik, Iceland.
Thorkell GudjonssonCancer Research Laboratory, Biomedical Center, Reykjavik, Iceland.
Jorunn EyfjordCancer Research Laboratory, Biomedical Center, Reykjavik, Iceland.
Jon JonassonFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Laufey TryggvadóttirFaculty of Medicine, University of Iceland, Reykjavik, Iceland.
Olafur StefanssonCurrent affiliation: deCODE genetics/Amgen Inc., Reykjavik, Iceland.
Stefan SigurdssonCancer Research Laboratory, Biomedical Center, Reykjavik, Iceland.
University of Iceland · ISdeCODE Genetics (Iceland) · ISInnovation Center Iceland · ISReykjavík University · IS

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Estrogen receptor-positive breast cancer is subdivided into subtypes LuminalA and LuminalB, based on different expression patterns. MicroRNA-190b has been reported to be up-regulated in estrogen receptor-positive breast cancers. In this study we aimed to investigate the role of CpG promoter methylation in regulating miR-190b expression and its impact on clinical presentation and prognosis. DNA methylation analysis for the promotor of microRNA-190b was performed by pyrosequencing 549 primary breast tumors, of which 62 were carriers of the

Indexed as

breast cancerDNA methylationestrogen receptormicroRNA-190bprognosis

Identifiers

PMID31384394
PMCPMC6659800
OpenAlexW2982991669

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.